Codagenix

Design Platform for Vaccine & Oncolytic Virus development. Vaccines: COVID, Flu, RSV, Dengue. Oncology: Breast Cancer and Solid Tumors

[Codagenix @Codagenix]

While this is an amazing achievement, the @gsk vaccines is only focused on preventing #RSV for older adults. @Codagenix is developing an #intranasal #vaccine for #pediatrics

[STAT @statnews]

#BREAKING: FDA approves first RSV vaccine, a long-sought scientific achievement https://t.co/zCdw9nJjMe #FDA #RSV

[Codagenix @Codagenix]

Dr. Jeffrey Fu, CBO, Codagenix, describes what is needed in next-generation COVID vaccines.

Our vaccine program strives address these factors as a live-attenuated, intranasal vaccine that induces an antibody and cell-mediated immunity (CMI).

Learn more: https://t.co/MsnloriRwg

[Codagenix @Codagenix]

Did you know? RSV poses a significant risk to children; more than half of RSV deaths occur in children ages 6 months and older.

Learn more about our work to develop an RSV vaccine for children: https://t.co/MsnloriRwg

[Codagenix @Codagenix]

Our live-attenuated #vaccines leverage proven manufacturing methods for widespread access and delivery.

Learn more: https://t.co/3Ju3xhIEEJ

[Codagenix @Codagenix]

At Codagenix, we're combining cutting-edge AI and #syntheticbiology to create safer, more effective live-attenuated #virus #vaccines. ️

Learn more: https://t.co/3Ju3xhIEEJ

[Codagenix @Codagenix]

Today, on International Day of Women and Girls in Science, we shine a spotlight on the incredible #womeninscience who push the boundaries of science and healthcare, including our very own Director of Preclinical Operations, Keri Wyllie, MPA.

Learn more: https://t.co/EeTDllxqz3

[Codagenix @Codagenix]

#ICYMI – Check this article from @ritarubin on @JAMA_current highlighting Codagenix's work on next-gen #vaccines, incl. those targeting the mucosal immune system via the nose, mimicking the natural infection route.

Read the full article: https://t.co/R0nLwAx8P6

[Codagenix @Codagenix]

Curious to learn about the biggest takeaways from #JPM24? Check out this article from @BioSpace that includes updates from Codagenix and many more.

Read here: https://t.co/RZXpC57RnB

#biopharma #biotech #innovation #healthcare

[Codagenix @Codagenix]

Codagenix CEO, Paul Grint, MD, was interviewed for this @WSJVC feature by Brian Gormley about the recent uptick in #biotech acquisitions.

Read here: https://t.co/CsQHMxFuXF

#biopharma #innovation #healthcare

[Codagenix @Codagenix]

#ICYMI - Codagenix was featured in this article from Jon Cohen (@sciencecohen) of @ScienceMagazine about Project NextGen, a U.S. government initiative investing billions in COVID-19 R&D.

Read the full article: https://t.co/NvXThQZbz4

[Codagenix @Codagenix]

Check out this article from @cwillyard in @techreview about the future of needle-free COVID #vaccines, and how Codagenix is among the companies leading the way.

https://t.co/7ooxFM6FbJ

[Codagenix @Codagenix]

Thank you @ritarubin and @JAMA_current for highlighting Codagenix's work on next-gen #vaccines, including those targeting the mucosal immune system via the nose, mimicking the natural route of the virus.

Read the full article: https://t.co/R0nLwAwAZy

[Codagenix @Codagenix]

This #JPM24, Codagenix’s CEO Paul Grint had the opportunity to speak with Tyler Patchen of @BioSpace about Codagenix’s live attenuated virus approach to #vaccine development.

Read the full article: https://t.co/GHIEFMnr4x

[Codagenix @Codagenix]

Team Codagenix is attending the 2024 JPMorgan Healthcare Conference in San Francisco, January 8-11. Contact us to schedule a meeting.

Learn more about our work: https://t.co/MsnloriRwg

#JPM2024 #JPM24

[Codagenix @Codagenix]

Dr. Johanna Kaufmann, EVP Oncology and Immunology, will be participating in a panel at the 8th Annual Oncolytic Virotherapy Summit on December 14 at noon ET. We hope to see you there!

Learn more: https://t.co/h4soAzb5cJ

[Codagenix @Codagenix]

#DYK that virotherapies have the potential to modulate the tumor microenvironment and trigger immune mechanisms to fight #cancer? At Codagenix, we explore novel #virotherapeutics for #breastcancer and other solid tumors.

Learn more about our pipeline: https://t.co/eT0VzlsWMB

[Codagenix @Codagenix]

Thank you @BioWorld for highlighting Codagenix’s @DeptofDefense award of $5.88 million to advance its tetravalent #dengue #vaccine program.

Learn more: https://t.co/EK5PyxK3hw

[Codagenix @Codagenix]

#ICYMI - Codagenix was featured in this article from Jon Cohen (@sciencecohen) of @ScienceMagazine about Project NextGen, a U.S. government initiative investing billions in COVID-19 R&D.

Read the full article: https://t.co/NvXThQZbz4

[Codagenix @Codagenix]

This Thanksgiving, we are #grateful for the incredible team of scientists and researchers at Codagenix who are dedicated to taking on the biggest threats in #infectiousdiseases and #cancer through our powerful codon-modification platform.

[Codagenix @Codagenix]

Dr. Johanna Kaufmann, EVP Oncology and Immunology, recently spoke to @sabrinaserani of @TargetedOnc about Codagenix’s #oncolytic #virotherapy platform.

Watch the full interview: https://t.co/ef1nmGSXq8

[Codagenix @Codagenix]

Today Codagenix announced the presentation of preclinical data for CodaLytic™, a codon-modified virus being developed for #breastcancer #immunovirotherapy, at the @sitcancer 38th Annual Meeting taking place November 1-5, 2023, in San Diego, California.

https://t.co/3Hoj01qjh2